Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Smilow Cancer Hospital at Yale–New Haven

Key Takeaway: The article provides an overview of Smilow Cancer Hospital at Yale-New Haven, detailing its management structure, collaborations, patient studies, and pipeline of drugs including Emavusertib and Fimepinostat. It also outlines resources for investors and career opportunities within the organization.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 27 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What is the focus of Smilow Cancer Hospital?

Smilow Cancer Hospital focuses on cancer treatment, research, and patient care.

What studies are currently sponsored by Smilow?

Current studies include TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What drugs are in the pipeline at Smilow?

The pipeline includes Emavusertib (CA-4948), Fimepinostat, CA-170, and CA-327.

How can investors find information about Smilow?

Investors can access press releases, SEC filings, and annual reports for information.

Last updated: Oct 23, 2024